75717-53-2

Basic information

• Product Name: Ethanone, 2-chloro-1-(2-hydroxy-5-methoxyphenyl)-
• Synonyms: 2-Chlor-1-(2-hydroxy-5-methoxy-phenyl)-aethanon;α-chloro-2-hydroxy-5-methoxyacetophenone;2-Hydroxy-5-methoxyphenacylchlorid;2-chloro-1-(2-hydroxy-5-methoxy-phenyl)-ethanone
• CAS NO: 75717-53-2
• Molecular Formula: C9H9ClO3
• Molecular Weight: 200.622
• Mol File: 75717-53-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 83-84 °C
• Boiling Point: 317.3±27.0 °C(Predicted)
• Density: 1.296±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ethanone, 2-chloro-1-(2-hydroxy-5-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-chloro-1-(2-hydroxy-5-methoxyphenyl)-(75717-53-2)
• EPA Substance Registry System: Ethanone, 2-chloro-1-(2-hydroxy-5-methoxyphenyl)-(75717-53-2)

Safety Data

• Hazardous Substances Data: 75717-53-2(Hazardous Substances Data)

Upstream product

• 1204-22-4 2-chloro-1-(2,5-dimethoxy-phenyl)-ethanone 
• 150-78-7 1,4-dimethoxybezene 
• 107-14-2 chloroacetonitrile 
• 150-76-5 4-methoxy-phenol 
• 59354-24-4 chloroacetonitrile 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 19278-82-1 5-hydroxy-2,3-dihydrobenzofuran-3-one 
• 13196-10-6 benzofuran-5-ol 
• 13391-28-1 5-methoxybenzofuran 
• 1427161-71-4 1H-imidazole-4-carbaldehyde [4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]hydrazone 
• 1427161-70-3 2-furaldehyde[4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]hydrazone 
• 1427161-68-9 1-benzofuran-2-carbaldehyde[4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]hydrazone 
• 1427161-66-7 1H-indole-3-carbaldehyde[4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]hydrazone 
• 1427161-65-6 2-naphthaldehyde-[4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]hydrazone 
• 1427161-67-8 imidazo[1,2-a]pyridine-3-carbaldehyde[4-(2-hydroxy-5-methoxyphenyl)-1,3-thiazol-2-yl]-hydrazone 
• 60912-82-5 α-chloro-2,5-dihydroxyacetophenone 
• 1248340-79-5 2-benzyl-5-methoxybenzo[b]furan 
• 99385-68-9 N-(4-acetylphenyl)-6-(aminomethyl)-5-hydroxy-2,3-dihydrobenzofuran 

Relevant articles and documents

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Evodiamine (Evo) is a quinazolinocarboline alkaloid found in Evodia rutaecarpa and exhibits moderate antiproliferative activity. Herein, we report using a scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options. The most potent compound 7f inhibited cell growth in a human breast carcinoma cell line (MDA-MB-231) with an IC50 value of 0.36 μM. Further studies revealed that Top1 was the target of 7f, which directly induced irreversible Top1-DNA covalent complex formation or induced an oxidative DNA lesion through an indirect mechanism mediated by reactive oxygen species. More importantly, in vivo studies showed that 7f exhibited potent antitumor activity in a TNBC-patient-derived tumor xenograft model. These results suggest that compound 7f deserves further investigation as a promising candidate for the treatment of TNBC.

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis

Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC50value of 3.15?μM. Subsequent SAR studies of hit compound 4 led to the development of novel benzofuran-3(2H)-one series of DRAK2 inhibitors with improved potency and favorable selectivity profiles against 26 selected kinases. Importantly, most potent compounds 40 (IC50?=?0.33?μM) and 41 (IC50?=?0.25?μM) were found to protect islet β-cells from apoptosis in dose-dependent manners. These data support the notion that small molecule inhibitors of DRAK2 represents a promising strategy for the treatment of diabetes.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.